Question 1

What is CagriSema?

Accepted Answer

CagriSema is the fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) in a single weekly injection, currently in Phase 3 trials.

Question 2

How does cagrilintide differ from GLP-1 agonists?

Accepted Answer

Cagrilintide targets amylin receptors in different brain regions than GLP-1 agonists, providing complementary satiety signaling through distinct neural pathways.

Question 3

Is cagrilintide FDA-approved?

Accepted Answer

Not yet. It is in Phase 3 clinical trials as both a standalone agent and in the CagriSema combination.

What is Cagrilintide - Peptide Encyclopedia